Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma

A Randomized Controlled Clinical Trial of Cytokine-induced Killer (CIK) Cells Treatment in Patients With Refractory Non-Hodgkin Lymphoma

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02497898

Enrollment

1000

Registered

2015-07-15

Start date

2015-07-31

Completion date

2040-07-31

Last updated

2015-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma, Non-Hodgkin

Brief summary

The purpose of this study is to study the safety and efficacy of chemotherapy usage followed by CIK transfusion in refractory and/or chemoresistant lymphomas.

Detailed description

Autologous cytokine-induced killer (CIK) cells transfusion(\>2\*10\^9 cells count) within 2 weeks after regular chemotherapy every 3 months.

Interventions

BIOLOGICALCytokine-induced killer cells (CIK)

Cytokine-induced killer (CIK) cells are able to eradicate lymphomas and other malignancies. CIK cells are generated by incubation of peripheral blood lymphocytes with an anti-cluster of differentiation 3 (anti-CD3) monoclonal antibody, interleukin-2 (IL-2), interleukin-1 (IL-1) and interferon-gamma.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* diagnosed as non-Hodgkin lymphoma with negative effect of regular chemotherapy, and need further therapy

Exclusion criteria

* patients refuse the therapy or have no tolerance for the therapy

Design outcomes

Primary

Measure	Time frame
Progression-Free-Survival (PFS)	1 month

Secondary

Measure	Time frame
Overall Survival (OS)	1 month

Other

Measure	Time frame
Lactic Dehydrogenase (LDH)	1 month

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026